Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Coherus BioSciences, Inc is a biotechnology business based in the US. Coherus BioSciences shares (CHRS) are listed on the NASDAQ and all prices are listed in US Dollars. Coherus BioSciences employs 306 staff and has a trailing 12-month revenue of around USD$487.4 million.
|Latest market close||USD$18.02|
|52-week range||USD$10.8616 - USD$23.03|
|50-day moving average||USD$18.4204|
|200-day moving average||USD$17.8309|
|Wall St. target price||USD$30.22|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$2.368|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-0.17%|
|1 month (2020-11-06)||8.03%|
|3 months (2020-09-04)||-2.22%|
|6 months (2020-06-05)||-4.25%|
|1 year (2019-12-05)||2.56%|
|2 years (2018-12-04)||76.15%|
|3 years (2017-12-05)||112.00%|
|5 years (2015-12-04)||-38.35%|
Valuing Coherus BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Coherus BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Coherus BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Coherus BioSciences shares trade at around 8x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Coherus BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$206.4 million.
The EBITDA is a measure of a Coherus BioSciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$487.4 million|
|Operating margin TTM||41.68%|
|Gross profit TTM||USD$244.9 million|
|Return on assets TTM||25.47%|
|Return on equity TTM||172.76%|
|Market capitalisation||USD$1.2 billion|
TTM: trailing 12 months
There are currently 17.8 million Coherus BioSciences shares held short by investors – that's known as Coherus BioSciences's "short interest". This figure is 5.9% down from 18.9 million last month.
There are a few different ways that this level of interest in shorting Coherus BioSciences shares can be evaluated.
Coherus BioSciences's "short interest ratio" (SIR) is the quantity of Coherus BioSciences shares currently shorted divided by the average quantity of Coherus BioSciences shares traded daily (recently around 964900.43454644). Coherus BioSciences's SIR currently stands at 18.41. In other words for every 100,000 Coherus BioSciences shares traded daily on the market, roughly 18410 shares are currently held short.
However Coherus BioSciences's short interest can also be evaluated against the total number of Coherus BioSciences shares, or, against the total number of tradable Coherus BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Coherus BioSciences's short interest could be expressed as 0.25% of the outstanding shares (for every 100,000 Coherus BioSciences shares in existence, roughly 250 shares are currently held short) or 0.3067% of the tradable shares (for every 100,000 tradable Coherus BioSciences shares, roughly 307 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Coherus BioSciences.
Find out more about how you can short Coherus BioSciences stock.
We're not expecting Coherus BioSciences to pay a dividend over the next 12 months.
Over the last 12 months, Coherus BioSciences's shares have ranged in value from as little as $10.8616 up to $23.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Coherus BioSciences's is 1.845. This would suggest that Coherus BioSciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.